US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB
BlockBeats News, July 28th, According to a report by businessinsider, Clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) today announced plans to strategically expand into the cryptocurrency and blockchain space.
The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to gradually raise and deploy up to $500 million in funds, with the goal of strategically long-term investing in BNB.
Liminatus emphasized that while the company remains fully committed to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is seen as a necessary step to support long-term growth and enhance shareholder value.
Liminatus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.
You may also like
Gainers
Latest Crypto News
Trump Says Fed Chair Should Cut Interest Rates, Reiterates Criticism of Powell
In the past 24 hours, the entire network liquidated $376 million, with the majority coming from the largest short position
The probability of a 25 basis point interest rate cut by the Federal Reserve in December is currently at 87.2%.
Trump: Will Announce New Fed Chair in Early Next Year
Coinbase International Site to Launch DASH Perpetual Contract Trading
Customer Support:@weikecs
Business Cooperation:@weikecs
Quant Trading & MM:[email protected]
VIP Services:[email protected]